Analysis and guidance from the Chicago Department of Public Health

New research shows that anti-retroviral drugs, long used to treat people infected with HIV/AIDS, can also prevent at-risk individuals from being infected with the virus in the first place. The most recent trial results in the Pre-exposure Prophy-laxis Initiative (iPrEx) represent a major breakthrough for HIV prevention, which has relied heavily on strategies to change behavior. HIV infects as many as 2.7 million people each year throughout the world.

According to the study published in the New England Journal of Medicine on No-vember 23, 2010, high-risk populations who received a daily dose of Pre-exposure Prophylaxis (PrEP) on average reduced their incidence of HIV infection by 43%.

The issues discussed here will be the source of much debate as the federal government determines how to best craft HIV prevention policy in light of the new developments.

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article’s content, whether in support or in opposition.]